

Trodelvy[™] (sacituzumab govitecan-hziy) – Indication withdrawal

- On October 18, 2024, <u>Gilead announced</u> plans to voluntarily withdraw the accelerated approval for <u>Trodelvy (sacituzumab govitecan-hziy)</u> for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
 - This decision was made in consultation with the FDA.
- This decision does not affect the other approved Trodelvy indications. Trodelvy is also approved for treatment of adult patients with:
 - Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease
 - Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
- Trodelvy was granted accelerated approval for mUC in 2021 based on tumor response rate and duration of response data from the single-arm TROPHY-U-01 study. Continued approval for this indication was contingent on verification and description of clinical benefit in the confirmatory TROPiCS-04 study.
 - As previously <u>announced</u>, the TROPiCS-04 study did not meet the primary endpoint of overall survival in the intention-to-treat population.
- Gilead will be notifying healthcare providers of this update. People receiving Trodelvy for mUC should discuss their care with their healthcare provider.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.